Home » News & Media » Press Releases » Sovereign Health Announces Three-Part Editorial Series on Opioid Addiction Implant Probhuphine

Sovereign Health Announces Three-Part Editorial Series on Opioid Addiction Implant Probhuphine

San Clemente, California – March 23, 2016 – Sovereign Health announces the launch of a new three-part editorial series focused on Probhuphine, an opioid subdermal implant for the treatment of opioid addiction. The inaugural article in this series takes an in-depth look at the use of the implant to treat opioid dependency; this is followed by part two, taking a look at the Food and Drug Administration’s (FDA) postponement on its decision to approve the implant. Amid the changing of the guard from the current Food and Drug commissioner to President Obama’s nomination, Robert Califf, M.D., the FDA halted its decision on approving the use of Probuphine, also known by its generic name, buprenorphine. To read the third article in this series, which details the resulting political showdown that leaves the opioid implant hanging in the balance, click HERE.

“As the opioid abuse rate continues to rise in the United States, claiming 40 lives a day with prescription opioid overdoses alone, specialists continue to advocate for innovative treatment options that will eliminate previous repercussions from other buprenorphine treatment,” said Rachael Mattice, managing editor for the Sovereign Health Group. “This editorial series takes a look at the current state of opioid addiction treatment and the continued debate surrounding the implant that the FDA has recently delayed for approval once again.”

The Centers for Disease Control and Prevention has labeled an epidemic of opioid abuse and overdoses plaguing the nation. According to a recent survey conducted by the American Society of Addiction Medicine, of physicians authorized to prescribe buprenorphine treatment, 66 percent report that consumer demand surpasses the stipulation of a 100-patient limit per physician. One solution has recently been unveiled: opioid addiction implants. Specifically, an implant called Probuphine.

To track this series, follow Sovereign Health on Facebook, LinkedIn or Twitter. Readers may also subscribe to Sovereign Health Group’s newsletter, a trusted source for news and developments on the topic of behavioral health. To read the March 2016 edition of the newsletter, click HERE. Sovereign Health will continue to educate professionals, patients and readers on subjects that affect the future of mental health and addiction treatment.

About the Sovereign Health Group

Sovereign Health Group’s mission has been to provide a broad spectrum of high-quality behavioral health treatment services. Sovereign Health’s treatment programs specialize in addressing underlying mental health conditions by utilizing innovative and cutting edge cognitive testing, rehabilitation and evidence-based treatment modalities. One factor that differentiates Sovereign from other treatment providers has been the company’s ability to offer separate mental health and addiction or dual diagnosis treatment programs at its nine facilities in Arizona, California, Florida, Utah, and Texas. Sovereign’s growth will continue in the coming year with additional facilities to be opened in California and Texas. The company’s national footprint will also expand with the opening of facilities in Massachusetts, New Jersey, Pennsylvania and Illinois. Sovereign Health Group offers high quality and comprehensive treatment programs for adults and adolescents, including support services for family members as well.


To learn more about Sovereign Health Group and its wide range of services, please contact Wendy Allen, Public Relations Manager, at 866-686-0090 or visit www.sovhealth.com

What Our Clients Say

©2016 SovHealth Treatment Centers. All Rights Reserved. (888) 530-4614 Privacy Policy Terms & Conditions Disclaimer
Close X
Live Chat Software